Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer

Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer

US Patent 10392444 · Granted Aug 27, 2019

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

MUC16 monoclonal antibody and uses thereof2023
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor as2022
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor as2022
Methods of increasing delivery of anti-cancer agents to targets2021
Methods of increasing delivery of anti-cancer agents to targets2021
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor as2020
Treatment of cancer with therapeutic monoclonal antibody specific for a tumor as2020
Methods for improving the bioactivity of therapeutic IgE antibodies for the trea2015
Polymeric nanoparticles for photosensitizers2014
IgE antibodies for the treatment of cancer2014
Method and device for photodynamic therapy2013
Combination therapy for treating disease2011